The company has struggled to keep up with the pace of its rivals Moderna and Pfizer, which make messenger RNA-based vaccines ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 ...

Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Novavax successfully operationalizing our partnership ... H5N1 virus has infected more than 70 persons in the United States and Canada and accounted for one death. We have developed a protein ...